What it is: A small synthetic peptide derived from angiotensin research, studied for its proposed role in supporting synaptic connections and cognitive function through the HGF/Met pathway.
Research suggests: Preclinical studies showed cognitive improvements described as exceptionally potent in comparisons with BDNF; human data is essentially absent.
Best for: Cognitive enhancement researchers
Key thing to know: One of the most poorly studied compounds in this library for humans - meaningful evidence is preclinical only, and human safety data does not exist.
What is Dihexa?
Dihexa (also known as PNB-0408) is a small synthetic peptide derived from angiotensin IV research , specifically from studies examining the hepatocyte growth factor (HGF) signaling system and its receptor Met, which play roles in neuronal survival, synaptic plasticity, and cognitive function. It was developed at Washington State University and gained significant attention in research circles for its reported potency relative to other cognitive enhancement compounds in preclinical studies.
Researchers study Dihexa for cognitive enhancement, synaptogenesis (formation of new synaptic connections), neurogenesis, and reversal of cognitive deficits in preclinical studies of neurodegeneration. Its reputation in the nootropic research community is built primarily on preclinical data and claims of exceptional potency , claims that require careful evaluation given the complete absence of human clinical trial data.
How it works.
Dihexa is proposed to act as a positive modulator of the HGF/Met signaling pathway , a system involved in neuronal growth, survival, and the formation of new synaptic connections. HGF/Met signaling promotes dendritic spine formation and synaptic plasticity , the structural changes in neurons that underlie learning and memory consolidation. Dihexa research suggests it may potentiate this pathway, potentially stimulating the growth of new synaptic connections in aging or cognitively compromised neural tissue.
Think of it as potentially amplifying the brain's own wiring and repair signaling system , encouraging neurons to form new connections rather than simply protecting existing ones. Some research has suggested Dihexa may be orders of magnitude more potent than BDNF (brain-derived neurotrophic factor) in certain in vitro synaptogenesis assays , a claim that has generated both significant scientific interest and significant scrutiny, since potency in cell assays does not reliably predict potency or even activity in living organisms.
The HGF/Met pathway is also relevant to cancer biology , Met is a proto-oncogene and HGF/Met signaling is involved in cell proliferation and survival in multiple tissue types. This dual biology is an important consideration in the risk assessment for any HGF/Met modulating compound, including Dihexa.
What the research shows.
Dihexa's evidence base is almost entirely preclinical. Rodent studies report significant improvements in spatial memory tasks (Morris water maze, radial arm maze), reversal of scopolamine-induced cognitive deficits, and improvement in aging-related cognitive decline models. The findings in preclinical studies have been consistent within the research group that developed the compound.
The potency claims , that Dihexa may be substantially more potent than BDNF in synaptogenesis assays , are based on in vitro cell culture data. In vitro potency comparisons are scientifically interesting but frequently do not translate to equivalent in vivo potency in living organisms, and even less reliably to human outcomes. No human clinical trials have been published as of 2025.
The complete absence of human data is the defining characteristic of Dihexa's evidence profile.
Biomarkers to review first.
These markers provide relevant baseline context for neurological health, stress response, and metabolic function before exploring Dihexa in a research context.
What it's commonly researched with.
In research contexts, Dihexa is most often discussed alongside other cognitive and neuroprotective compounds that target complementary neurological pathways. These combinations appear in community research discussions , not formal published combination trials.